Anastasiou Vasileios, Daios Stylianos, Moysidis Dimitrios V, Bazmpani Maria-Anna, Zegkos Thomas, Karamitsos Theodoros, Makedou Kali, Savopoulos Christos, Efthimiadis Georgios, Ziakas Antonios, Kamperidis Vasileios
First Department of Cardiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Laboratory of Biochemistry, AHEPA Hospital, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
Diagnostics (Basel). 2023 Mar 21;13(6):1191. doi: 10.3390/diagnostics13061191.
Despite ongoing treatment advancements in chronic heart failure (HF), mortality and readmission rates remain high for patients hospitalized for decompensated acute HF. These patients represent a distinct HF group, which requires emergent echocardiographic evaluation in an attempt to provide optimal and individualized acute care. The role of serial advanced echocardiographic assessment in acute HF for risk stratification and treatment guidance has not been thoroughly explored.
The "Beyond Myo-HF Study" is a prospective, non-interventional cohort trial designed to enroll acutely admitted patients with symptoms and/or signs of HF. The aim of this study is to investigate whether intrahospital changes of conventional and novel echocardiographic indices of myocardial function and congestion-related markers can predict early mortality, late mortality, and HF rehospitalization. As per the protocol, all patients undergo a pair of state-of-the-art echocardiographic assessments, with a rigorous protocol including speckle tracking analysis of all cardiac chambers and myocardial work analysis for the left and right ventricle, upon admission and pre-discharge. Their laboratory profile is captured at those two time-points, and their therapeutic management is recorded. Patients will be followed-up for a median period of 12 months after enrollment.
The "Beyond Myo-HF" study is an ongoing, prospective trial aspiring to provide deep insight into the pathophysiology of acute HF, to enlighten the reverse cardiac functional and anatomical remodeling during hospitalization, and to recognize echocardiographic patterns capable of predicting adverse outcomes during and post decompensation of acute HF.
尽管慢性心力衰竭（HF）的治疗不断取得进展，但因急性失代偿性 HF 住院的患者死亡率和再入院率仍然很高。这些患者代表了一个独特的 HF 群体，需要进行紧急超声心动图评估，以提供最佳的个体化急性治疗。连续进行高级超声心动图评估在急性 HF 中用于风险分层和治疗指导的作用尚未得到充分探索。
“超越心肌 HF 研究”是一项前瞻性、非干预性队列试验，旨在纳入有 HF 症状和/或体征的急性入院患者。本研究的目的是调查心肌功能和充血相关标志物的传统及新型超声心动图指标的院内变化是否能预测早期死亡率、晚期死亡率和 HF 再住院情况。根据方案，所有患者在入院时和出院前均接受一对最先进的超声心动图评估，采用严格的方案，包括对所有心腔进行斑点追踪分析以及对左心室和右心室进行心肌工作分析。在这两个时间点采集他们的实验室检查结果，并记录他们的治疗管理情况。患者入组后将进行为期 12 个月的中位随访。
“超越心肌 HF”研究是一项正在进行的前瞻性试验，旨在深入了解急性 HF 的病理生理学，阐明住院期间心脏功能和解剖结构的逆向重塑，并识别能够预测急性 HF 失代偿期间及之后不良结局的超声心动图模式。
